Pharma BD Deal Intelligence

GlaxoSmithKline plc / Adaptimmune Therapeutics plc

2014 · Co-Development · $350M · Terminated

GSK and Adaptimmune signed a strategic collaboration covering up to five engineered TCR cell-therapy programs led by NY-ESO-1, with potential payments up to $350M over seven years. The deal validated Adaptimmune's SPEAR platform and was the foundation for letetresgene autoleucel; ultimately wound down by GSK in 2024.

Key facts

• Announced Jun 26, 2014
• Closed Jun 26, 2014
• Deal value $350M
• Deal type Co-Development
• Therapeutic area Synovial sarcoma, multiple myeloma, melanoma and other NY-ESO-1+ solid tumors
• Indications Synovial sarcoma, multiple myeloma, melanoma and other NY-ESO-1+ solid tumors
• Key assets Affinity-enhanced TCR therapy targeting NY-ESO-1
• Mechanism Engineered autologous T-cell receptor (SPEAR) cell therapy

← Browse all deals  ·  How we score deals